Document is current
Any future updates will be listed below
-
Authors
Furube, Tasuku
Takeuchi, Masashi
Kawakubo, Hirofumi
Noma, Kazuhiro
Maeda, Naoaki
Daiko, Hiroyuki
Ishiyama, Koshiro
Otsuka, Koji
Sato, Yoshihito
Koyanagi, Kazuo
Tajima, Kohei
Garcia, Rodrigo Nicida
Maeda, Yusuke
Matsuda, Satoru
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 18 June 2024
Accepted: 23 August 2024
First Online: 12 September 2024
Disclosures
: Yuko Kitagawa reports grants and personal fees from ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Factory, Inc., and Nippon Covidien Inc.; grants, personal fees, and others from ONO PHARMACEUTICAL CO., LTD, TAIHO PHARMACEUTICAL CO., LTD, and CHUGAI PHARMACEUTICAL CO., LTD.; grants and personal fees from KAKEN PHARMACEUTICAL CO., LTD.; personal fees from AstraZeneca K.K., Ethicon Inc., Olympus Corporation, SHIONOGI & CO., LTD., Bristol-Myers Squibb K.K., MSD K.K., Smith & Nephew KK, ASKA Pharmaceutical Co., Ltd., MIYARISAN PHARMACEUTICAL CO., LTD., Toray Industries, Inc., DAIICHI SANKYO COMPANY, LIMITED, Chugai Foundation for Innovative Drug Discovery Science, and Nippon Kayaku Co., Ltd.; grants from Yakult Honsha Co., Ltd., TSUMURA & CO., and Sumitomo Pharma Co., Ltd.; grants and personal fees from EA Pharma Co.; Ltd., grants from Eisai Co., Ltd., Kyowa Kirin Co., Ltd., MEDICON INC., Takeda Pharmaceutical Co., Ltd., and TEIJIN PHARMA LIMITED; and personal fees from Intuitive Surgical G.K. outside the submitted work. Yuko Kitagawa and Yusuke Maeda have equity for Direava.inc. Masashi Takeuchi is a chief executive officer for Direava.inc.
